Andigensil Biotechnology
Wuhan, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Chinese supplier of animal-derived biological raw materials for IVD and pathological diagnostics, not a clinical-stage gene or cell therapy company.
Gene TherapyCell TherapyOncology
Technology Platform
Platform for the purification and production of animal-derived biological raw materials, including affinity chromatography for antibodies and proprietary formulations for immunohistochemistry and diagnostic blockers.
Opportunities
Growth is tied to the expanding global IVD and pathological diagnostics market, with opportunities in supplying raw materials for next-generation diagnostic assays and expanding their patented IHC product line.
Risk Factors
Key risks include dependence on animal sourcing, regulatory scrutiny for animal-derived materials, intense competition in the reagent supply market, and potential supply chain disruptions.
Competitive Landscape
Competes with numerous global and Chinese biological reagent suppliers (e.g., Thermo Fisher, Abcam, Sino Biological). Differentiation is claimed through proprietary IHC kits, a self-supported animal base, and high-purity animal IgG products.